These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35271413)

  • 1. Retrospective single-center experience with OEPA/COPDAC and PET-CT based strategy for pediatric Hodgkin lymphoma in a LMIC setting.
    Palayullakandi A; Trehan A; Jain R; Kumar R; Mittal BR; Kapoor R; Srinivasan R; Kakkar N; Bansal D
    Pediatr Hematol Oncol; 2022 Oct; 39(7):587-599. PubMed ID: 35271413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
    Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
    Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary.
    McLaughlin M; Kelsey TW; Wallace WH; Anderson RA; Telfer EE
    Hum Reprod; 2017 Jan; 32(1):165-174. PubMed ID: 27923859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of clinical features and treatment outcomes of children with Hodgkin's Lymphoma treated with different chemotherapy protocols at a tertiary care center in Pakistan.
    Mehreen A; Wali RM; Sindhu II; Asad M; Ria S
    J Pak Med Assoc; 2019 Sep; 69(9):1266-1272. PubMed ID: 31511710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response assessment by positron emission tomography-computed tomography as compared with contrast-enhanced computed tomography in childhood Hodgkin lymphoma can reduce the need for radiotherapy in low- and middle-income countries.
    Kalra M; Bakhshi S; Singh M; Seth R; Verma N; Jain S; Radhakrishnan V; Mandal P; Mahajan A; Arora RS; Dinand V; Kapoor G; Sajid M; Kumar R; Taluja A; Mallick S; Chandra J
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30091. PubMed ID: 36411263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian Hormone.
    Drechsel KCE; Broer SL; Stoutjesdijk FS; van Dulmen-den Broeder E; Beishuizen A; Wallace WH; Körholz D; Mauz-Körholz C; Hasenclever D; Cepelova M; Uyttebroeck A; Ronceray L; Twisk JWR; Kaspers GJL; Veening MA
    Hum Reprod; 2024 May; ():. PubMed ID: 38794915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study.
    Mauz-Körholz C; Landman-Parker J; Fernández-Teijeiro A; Attarbaschi A; Balwierz W; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Ceppi F; Claviez A; Daw S; Dieckmann K; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH; Kluge R
    Lancet Oncol; 2023 Mar; 24(3):252-261. PubMed ID: 36858722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD.
    Ingley KM; Nadel HR; Potts JE; Wilson DC; Eftekhari A; Deyell RJ
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):e87-e93. PubMed ID: 31259825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India.
    Parambil BC; Narula G; Prasad M; Shah S; Shet T; Shridhar E; Khanna N; Laskar S; Gujral S; Sankaran H; Banavali S
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28058. PubMed ID: 31724304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
    Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
    J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma.
    Ozuah NW; Marcus KJ; LaCasce AS; Billett AL
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):e338-e342. PubMed ID: 29293187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
    Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
    Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Delarue R; Farhat H; Quittet P; Berriolo-Riedinger A; Tempescul A; Edeline V; Maisonneuve H; Fornecker LM; Lamy T; Delmer A; Dartigues P; Martin L; André M; Mounier N; Traverse-Glehen A; Meignan M
    Lancet Oncol; 2019 Feb; 20(2):202-215. PubMed ID: 30658935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
    Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
    Milgrom SA; Pinnix CC; Chuang H; Oki Y; Akhtari M; Mawlawi O; Garg N; Gunther JR; Reddy JP; Smith GL; Rohren E; Hagemeister FB; Lee HJ; Fayad LE; Dong W; Osborne EM; Abou Yehia Z; Fanale M; Dabaja BS
    Br J Haematol; 2017 Nov; 179(3):488-496. PubMed ID: 28832956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study.
    Chugh S; Panda G; Mokal S; Jain H; Bagal B; Khanna N; Epari S; Punatar S; Nayak L; Gokarn A; Khattry N; Sengar M; Laskar S; Goda JS
    Indian J Med Res; 2024 Feb; 159(2):193-205. PubMed ID: 38577858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.
    Metzger ML; Weinstein HJ; Hudson MM; Billett AL; Larsen EC; Friedmann A; Howard SC; Donaldson SS; Krasin MJ; Kun LE; Marcus KJ; Yock TI; Tarbell N; Billups CA; Wu J; Link MP
    JAMA; 2012 Jun; 307(24):2609-16. PubMed ID: 22735430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
    Santoro A; Mazza R; Spina M; Califano C; Specchia G; Carella M; Consoli U; Palombi F; Musso M; Pulsoni A; Kovalchuk S; Bonfichi M; Ricci F; Fabbri A; Liberati AM; Rodari M; Giordano L; Chimienti E; Balzarotti M; Sorasio R; Gallamini A; Ghiggi C; Ciammella P; Ricardi U; Chauvie S; Carlo-Stella C; Merli F
    Ann Hematol; 2021 Oct; 100(10):2547-2556. PubMed ID: 34327561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.